|Bid||61.63 x 3000|
|Ask||62.02 x 1000|
|Day's Range||61.61 - 63.58|
|52 Week Range||57.17 - 74.12|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||18.87|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs. In a statement, Gilead has identified and named as defendants two individuals responsible for leading and orchestrating the counterfeit scheme. The company initiated this litigation in July 2021 to halt the distribution of counterfeits. A court filing uncovered an opera
A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged "kingpins." Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since last year, said in a court filing unsealed on Wednesday it had uncovered an operation that was "staggering in scope," responsible for sales of hundreds of millions of dollars of counterfeit bottles of its top sellers Descovy, Genvoya and Biktarvy, and other medicines. U.S. District Judge Ann Donnelly's latest asset freeze order, also unsealed on Wednesday, targets more than 50 defendants newly added to Gilead's lawsuit.
To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...